ViaNautis is transforming cell and gene therapy with targeted polyNaut® nanovesicles (tPNVs)
ViaNautis is committed to advancing programmes that make advanced genetic therapies more effective, affordable, and accessible, bringing life-changing treatments to patients in need.
Established as SomaServe as a UCL spin-out in 2018, the company now consists of an exceptional team of scientists and biotech leaders working from state-of-the-art facilities in Cambridge, UK.
Our Team
Dr Adi Hoess
Dr Adi Hoess brings over two decades of experience in biotechnology.
Dr Ray Jupp
Over 25 years of leadership experience in both biotech and pharmaceutical industries
Dr Samuel Barker
Expertise in developing and commercialising innovative platform technologies.
Dr Denis Cecchin
Skilled in Translational research, research and development, and Business Development.
Dr Sarah Wythe
Expertise in advanced therapeutic platforms to guide the company’s pioneering work in genetic medicine.
Sam Smart
Over 20 years of board-level experience spanning finance, strategy and operations in life sciences companies
Board of Directors
ViaNautis is guided by a board of seasoned experts in biotechnology, finance, and innovation. Their strategic oversight and industry experience help steer the Company’s mission to advance cutting-edge genetic medicines
Dr Adi Hoess
Dr Adi Hoess brings over two decades of experience in biotechnology.
Steven Altschuler
Steven Altschuler brings nearly 25 years of experience building and leading world-class, integrated, translational, value-based health care systems and transformational biotechnology companies.
Investors
ViaNautis is supported by a dedicated and forward-thinking group of investors who share the Company’s vision of making advanced genetic therapies more effective, affordable, and accessible
